SCHEMBL11923288

SCHEMBL11923288

O=C(c1cnc(N2CCOCC2)nc1-c1ccccc1F)N1CCCC(c2ccc(F)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ PROKR1 Q8TCW9 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ BCR P11274 2/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CASP1 P29466 2/20 0.41
▸ CASP7 P55210 2/20 0.41
▸ HIF1A Q16665 2/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8268278 0.86 ABL1 (0.52) ALDH1A1TP53ABL1BCRPOLB
SCHEMBL8267373 0.85 ABL1 (0.51) ALDH1A1TP53ABL1BCRPOLB
SCHEMBL8266822 0.85 LMNA (0.40) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL8267844 0.84 ABL1 (0.53) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL11923375 0.82 KDM4E (0.48) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL8267367 0.81 ABL1 (0.45) ALDH1A1TP53ABL1BCRLMNA
SCHEMBL8266816 0.81 ABL1 (0.48) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL8267325 0.79 ALDH1A1 (0.44) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL8265841 0.79 MAPT (0.47) ALDH1A1KMT2ATP53MEN1ABL1
SCHEMBL2948308 0.78 PTPN11 (0.52) ALDH1A1KMT2ATP53MEN1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546414-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-01 — — US disclosed
US-8546414-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-10-01 — — US disclosed
US-20120270318-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 — — US disclosed
US-20120270318-A1 ION CHANNEL MODULATORS AND METHODS OF USE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-25 — — US disclosed
US-8236815-B2 Ion channel modulators and methods of uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-07 — — US disclosed
US-8236815-B2 Ion channel modulators and methods of uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-07 — — US disclosed
US-7767680-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-03 — — US disclosed
US-7767680-B2 Ion channel modulators and methods of use VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-03 — — US disclosed
US-20100184753-A1 Ion Channel Modulators and Methods of Uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 — — US disclosed
US-20100184753-A1 Ion Channel Modulators and Methods of Uses VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184753-A1 Ion Channel Modulators and Methods of Uses CACNA1G, CACNA1C, CACNA1B ALDH1A1 3514/4885KMT2A 2786/4885PROKR1 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback